Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential Efficacy of Alpelisib by PIK3CA Mutation Site in Head and Neck Squamous Cell Carcinoma: An Analysis from the KCSG HN 15-16 TRIUMPH Trial

31 Jan 2025

Abstract excerpt

PURPOSE: The TRIUMPH trial was a biomarker-driven umbrella trial for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). This analysis focuses on the PIK3CAα (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) inhibitor alpelisib (arm 1) in patients with phosphoinositide 3-kinase (PI3K) pathway alterations. MATERIALS AND METHODS: Patients with PI3K pathway...

Topics

Join the communities discussing this publication.

Head and Neck Cancer Studies
Hippo pathway signaling and YAP/TAZ
PI3K/AKT/mTOR signaling in cancer

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 39901702
DOI: 10.4143/crt.2024.1195

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential Efficacy of Alpelisib by PIK3CA Mutation Site in Head and Neck Squamous Cell Carcinoma: An Analysis from the KCSG HN 15-16 TRIUMPH TrialPMID 39901702Read ↗

Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.Semantic proximity Read ↗

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers.Semantic proximity Read ↗

Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trial.Semantic proximity Read ↗

Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.Semantic proximity Read ↗

Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.Semantic proximity Read ↗

Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)Semantic proximity Read ↗

Exploiting the Head and Neck Cancer Oncogenome: Widespread PI3K-mTOR Pathway Alterations and Novel Molecular TargetsSemantic proximity Read ↗

HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma.Semantic proximity Read ↗

Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.Semantic proximity Read ↗

Oncogenic driver mutations predict outcome in a cohort of head and neck squamous cell carcinoma (HNSCC) patients within a clinical trial.Semantic proximity Read ↗

IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck CancerSemantic proximity Read ↗

PIK3CA somatic mutations as potential biomarker for immunotherapy in elder or TP53 mutated gastric cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.